MNKD
NASDAQMannKind Corporation
News · 26 weeks570%
2026-04-192026-10-11
Mix1790d
- Other6(35%)
- Earnings4(24%)
- SEC Filings4(24%)
- Insider3(18%)
Latest news
25 items- PRMannKind to Participate in the Chardan Healthcare ConferenceDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on innovation across chronic respiratory diseases at the Chardan Healthcare Conference. Management will also participate in one-on-one meetings with investors during the conference. Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, CF, Bronchiectasis & COPD InnovationDate: Tuesday, October 20, 2026Time: 2:00–2:30 p.m. ET A live webcast of the panel discussion will be available on the Events & Presentations section of MannKind’s Investor Relations
- PRMannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemideConsistent bioavailability, diuresis and natriuresis across injection sites support flexible administration in clinical practiceCross-study analysis demonstrates comparable diuretic and natriuretic responses between Furoscix ReadyFlow and Furoscix® (furosemide) On-body Infusor, supporting a seamless transition to ReadyFlowData presentations build on the July 2026 FDA approval and U.S. launch of Furoscix ReadyFlow, the first and only autoinjector delivering IV-equivalent diuretic therapy for heart failure- and CKD-related edema (fluid overload) WESTLAKE VILL
- INSIDERDirector Binder Steven B. sold $128,478 worth of shares (39,051 units at $3.29), decreasing direct ownership by 5% to 713,258 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERDirector Binder Steven B. sold $127,856 worth of shares (33,558 units at $3.81), decreasing direct ownership by 4% to 752,309 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- PRMannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight ManagementCollaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, and Rose Pharma Inc. (Rose Pharma) today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Tech
- PRMannKind to Present at Upcoming Investor ConferencesDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences: Cantor Global Healthcare Conference (New York, NY)Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET Links to the live audio webcasts of the presentations will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. A recorded version will also be available o
- SECSEC Form 8-K filed by MannKind Corporation8-K - MANNKIND CORP (0000899460) (Filer)
- SECSEC Form 424B7 filed by MannKind Corporation424B7 - MANNKIND CORP (0000899460) (Filer)
- INSIDERDirector Binder Steven B. sold $158,547 worth of shares (39,051 units at $4.06), decreasing direct ownership by 5% to 785,867 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- SECSEC Form 10-Q filed by MannKind Corporation10-Q - MANNKIND CORP (0000899460) (Filer)
- SECMannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MANNKIND CORP (0000899460) (Filer)
- PRMannKind Reports Second Quarter 2026 Financial Results and Provides Business UpdateAchieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza® following FDA approvalFUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKDPositive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement Encouraging early momentum in Afrezza pediatric launch 1 in 3 of the top 100 pediatric insulin writers have prescribed Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025Conference call and webcast today at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD)a biopharmaceutical company dedicated to tr
- PRMannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPFGenerally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered in patients with IPFGlobal Phase 2 INFLO-2 trial actively enrolling patientsConference call and webcast scheduled for July 29 at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced positive topline results from INFLO-1, its Phase 1b randomized, double-blind, placebo-controlled study evaluating
- PRMannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026. MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update. The webcast of the conference call will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in the same location within 24 hours following the call and will be accessible for approximately 90 days. About MannKind MannK
- SECSEC Form 8-K filed by MannKind Corporation8-K - MANNKIND CORP (0000899460) (Filer)
- PRMannKind Announces $50 Million Private PlacementDANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it has entered into a securities purchase agreement in connection with a private placement to certain institutional investors. The gross proceeds from the private placement financing are expected to be approximately $50 million. The closing of the financing is expected to occur on or about July 24, 2026, subject to the satisfaction of customary closing conditions. The private placement was l
- PRMannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney DiseaseTransformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital settingDelivers IV-equivalent diuretic effect through a simple, ready-to-use autoinjectorProvides an 80 mg/mL furosemide dose in a single administration in under 10 secondsSymptom relief may begin in an hour or lessConference call and webcast scheduled for July 24 at 9:00 a.m. ET WESTLAKE VILLAGE, Calif., and BOSTON, July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic an
- INSIDERChief Financial Officer Prentiss Christopher B covered exercise/tax liability with 22,247 shares, decreasing direct ownership by 7% to 318,668 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERPres, Endocrine Business Unit Marasco Dominic covered exercise/tax liability with 3,623 shares, decreasing direct ownership by 1% to 343,398 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief People & Workpl Officer Tross Stuart A converted options into 93,790 shares and covered exercise/tax liability with 65,808 shares, increasing direct ownership by 3% to 1,058,142 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief Executive Officer Castagna Michael converted options into 350,260 shares and covered exercise/tax liability with 363,200 shares, decreasing direct ownership by 0.53% to 2,433,779 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDEREVP Technical Operations Singh Sanjay R converted options into 70,550 shares and covered exercise/tax liability with 46,795 shares, increasing direct ownership by 5% to 478,966 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDEREVP Genl Counsel & Secretary Thomson David covered exercise/tax liability with 98,426 shares, sold $97,641 worth of shares (24,109 units at $4.05) and converted options into 93,790 shares, decreasing direct ownership by 3% to 797,554 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERDirector Binder Steven B. sold $213,089 worth of shares (52,485 units at $4.06), converted options into 93,790 shares and covered exercise/tax liability with 24,395 shares, increasing direct ownership by 2% to 824,918 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- PRMannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1DCollaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced it has been awarded a grant from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes (T1D) research and advocacy organization, through its Industry Discovery and Development Partnership (IDDP) program, to support the ongoing INHALE-1ST clinical study evaluati
MNKD FAQ
7 questionsWhat does MannKind Corporation do?
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary...Where does MNKD stock trade?
MannKind Corporation (MNKD) is listed on NASDAQ.What sector and industry is MNKD in?
MannKind Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MannKind Corporation go public?
MannKind Corporation (MNKD) completed its IPO in 2004.What are analysts saying about MNKD?
MannKind Corporation has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform with a $350.00 price target on 2026-02-27. Recent price targets range from $350.00 to $1200.00.What companies are similar to MNKD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MNKD side-by-side with any of them on Quantisnow.How can I track MNKD on Quantisnow?
Quantisnow aggregates MannKind Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNKD to receive live email and push alerts on every new disclosure.